FMS-like Tyrosine Kinase 3 (FLT3) Amplification in Patients with Metastatic Colorectal Cancer

Overview

Journal Cancer Sci

Specialty Oncology

Date 2020 Oct 19

PMID 33075166

Citations 10

Authors

Hiroko Hasegawa

Hiroya Taniguchi

Yoshiaki Nakamura

Takeshi Kato

Satoshi Fujii

Hiromichi Ebi

Manabu Shiozawa

Satoshi Yuki

Toshiki Masuishi

Ken Kato

Naoki Izawa

Toshikazu Moriwaki

Eiji Oki

Yoshinori Kagawa

Tadamichi Denda

Tomohiro Nishina

Akihito Tsuji

Hiroki Hara

Taito Esaki

Tomohiro Nishida

Hisato Kawakami

Yasutoshi Sakamoto

Izumi Miki

Wataru Okamoto

Kentaro Yamazaki

Takayuki Yoshino

Affiliations

Soon will be listed here.

Abstract

FMS-like tyrosine kinase 3 (FLT3) plays a key role in hematopoiesis. However, the oncogenic role of FLT3 amplification in patients with metastatic colorectal cancer (mCRC) remains unclear. Here, we aimed to evaluate the characteristics, prognosis, and treatment efficacy of an FLT3 inhibitor (regorafenib) in patients with mCRC with FLT3 amplifications. Tumor tissue samples from 2329 patients were sequenced using NGS in the Nationwide Cancer Genome Screening Project in Japan. The effects of clinicopathological features, co-altered genes, prognosis, and efficacy of regorafenib were investigated. Between April 2015 and June 2018, 85 patients with mCRC with FLT3 amplification were observed. There were no differences in baseline characteristics between patients with or without FLT3 amplification. The frequency of RAS or other gene co-alterations was inversely correlated with the copy number status. Median survival time in patients with FLT3 amplification was significantly shorter compared with those with non-FLT3 amplification. Further investigations of FLT3 amplification as a potential treatment target in mCRC are warranted.

Citing Articles

CLG promotes mTOR/ULK1 pathway-mediated autophagy to inhibit OS development by inhibiting TRAF6-mediated FLT3 ubiquitination.

Huang X, Huang Y, Peng B, Wang J, Tang H, Chen Y Cancer Sci. 2024; 115(10):3466-3480.

PMID: 39118482 PMC: 11447880. DOI: 10.1111/cas.16274.

Case report: Precision guided reactive cancer management: molecular complete response in heavily pretreated metastatic CRC by dual immunotherapy and sorafenib.

Aydin E, Tokat U, Adibi A, Ozgu E, Bilgic S, Demiray M Front Oncol. 2024; 14:1405170.

PMID: 39011472 PMC: 11246968. DOI: 10.3389/fonc.2024.1405170.

FLT3-Mutated Leukemic Stem Cells: Mechanisms of Resistance and New Therapeutic Targets.

Capelli D Cancers (Basel). 2024; 16(10).

PMID: 38791898 PMC: 11119130. DOI: 10.3390/cancers16101819.

Case Report: Progressive disease of BRCA2-mutant colon adenocarcinoma following talazoparib therapy.

Polyanskaya E, Lebedeva A, Kuznetsova O, Belova E, Kavun A, Ivanov M Front Oncol. 2023; 13:1245547.

PMID: 38023256 PMC: 10662308. DOI: 10.3389/fonc.2023.1245547.

A novel immune score model predicting the prognosis and immunotherapy response of breast cancer.

Lv W, He X, Wang Y, Zhao C, Dong M, Wu Y Sci Rep. 2023; 13(1):6403.

PMID: 37076508 PMC: 10115816. DOI: 10.1038/s41598-023-31153-2.

References

De La Fouchardiere C . Regorafenib in the treatment of metastatic colorectal cancer. Future Oncol. 2018; 14(22):2239-2246. DOI: 10.2217/fon-2017-0512. View

Williams B, Atkins A, Zhang H, Lu D, Jimenez X, Li H . Cell-based selection of internalizing fully human antagonistic antibodies directed against FLT3 for suppression of leukemia cell growth. Leukemia. 2005; 19(8):1432-8. DOI: 10.1038/sj.leu.2403825. View

. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014; 511(7511):543-50. PMC: 4231481. DOI: 10.1038/nature13385. View

Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M . Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2012; 381(9863):303-12. DOI: 10.1016/S0140-6736(12)61900-X. View

Ofarrell A, Abrams T, Yuen H, Ngai T, Louie S, Yee K . SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood. 2003; 101(9):3597-605. DOI: 10.1182/blood-2002-07-2307. View

Wilhelm S, Dumas J, Adnane L, Lynch M, Carter C, Schutz G . Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2010; 129(1):245-55. DOI: 10.1002/ijc.25864. View

Hasegawa H, Taniguchi H, Nakamura Y, Kato T, Fujii S, Ebi H . FMS-like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer. Cancer Sci. 2020; 112(1):314-322. PMC: 7780005. DOI: 10.1111/cas.14693. View

. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012; 487(7407):330-7. PMC: 3401966. DOI: 10.1038/nature11252. View

Moreira R, Peixoto R, Cruz M . Clinical Response to Sorafenib in a Patient with Metastatic Colorectal Cancer and FLT3 Amplification. Case Rep Oncol. 2015; 8(1):83-7. PMC: 4361904. DOI: 10.1159/000375483. View

10.

Scholl C, Gilliland D, Frohling S . Deregulation of signaling pathways in acute myeloid leukemia. Semin Oncol. 2008; 35(4):336-45. DOI: 10.1053/j.seminoncol.2008.04.004. View

11.

Wilhelm S, Carter C, Tang L, Wilkie D, McNabola A, Rong H . BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004; 64(19):7099-109. DOI: 10.1158/0008-5472.CAN-04-1443. View

12.

Armstrong S, Kung A, Mabon M, Silverman L, Stam R, den Boer M . Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell. 2003; 3(2):173-83. DOI: 10.1016/s1535-6108(03)00003-5. View

13.

. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490(7418):61-70. PMC: 3465532. DOI: 10.1038/nature11412. View

14.

Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G . Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med. 2015; 21(7):795-801. PMC: 4868598. DOI: 10.1038/nm.3870. View

15.

Blume-Jensen P, Hunter T . Oncogenic kinase signalling. Nature. 2001; 411(6835):355-65. DOI: 10.1038/35077225. View

16.

Janjigian Y, Tang L, Coit D, Kelsen D, Francone T, Weiser M . MET expression and amplification in patients with localized gastric cancer. Cancer Epidemiol Biomarkers Prev. 2011; 20(5):1021-7. PMC: 3690490. DOI: 10.1158/1055-9965.EPI-10-1080. View

17.

Go H, Jeon Y, Park H, Sung S, Seo J, Chung D . High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer. J Thorac Oncol. 2010; 5(3):305-13. DOI: 10.1097/JTO.0b013e3181ce3d1d. View

18.

. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014; 513(7517):202-9. PMC: 4170219. DOI: 10.1038/nature13480. View

19.

Sawada K, Nakamura Y, Yamanaka T, Kuboki Y, Yamaguchi D, Yuki S . Prognostic and Predictive Value of HER2 Amplification in Patients With Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2018; 17(3):198-205. DOI: 10.1016/j.clcc.2018.05.006. View

20.

Lim S, Kim S, Kim K, Jang H, Ahn S, Kim K . The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors. Oncotarget. 2016; 8(2):3237-3245. PMC: 5356878. DOI: 10.18632/oncotarget.13700. View